Boston University developed a methodology to evaluate the impact of Novartis Access in Kenya. Peter C. Rockers tells us about the ongoing study.

Researchers race to put hydroxychloroquine to the test in a large study.

Explaining Chagas disease through the stories of patients in Latin America.

Chronic diseases like cancer and diabetes were once the preserve of wealthy countries but are now increasingly common in lower-income countries too as populations age and lifestyles change.

Most people have never heard of spinal muscular atrophy (SMA), a rare genetic disease that affects approximately 1 in 6,000 babies born worldwide each year. Innovative research may produce treatments for patients suffering from SMA and other rare diseases.

Three years after discussing how to reuse an old scientific measuring device, Novartis scientists are now testing this idea as part of an innovative research project.

Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.

The cause of a rare, inherited, often fatal kidney disease in many patients remained elusive for years, despite multiple attempts to solve the mystery. Then in 2012, a team of researchers cracked some of the unsolved cases in just six weeks.

Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.